Trials / Not Yet Recruiting
Not Yet RecruitingNCT07486310
Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Guangdong Provincial People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a prospective, multicenter, open-label, randomized controlled clinical trial, planned to enroll 30 patients with advanced gastric cancer and peritoneal metastasis. It aims to evaluate the safety and efficacy of systemic therapy plus Pressurized Intra-Peritoneal Aerosol Virus (PIPAV) with VRT106 compared to systemic therapy plus Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC).
Detailed description
To evaluate the efficacy and quality of life in different treatment cohorts for patients with advanced gastric cancer and peritoneal metastasis. To evaluate the biodistribution and biological effects of PIPAV（Pressurized Intra-Peritoneal Aerosol Virus） treatment in patients with advanced gastric cancer and peritoneal metastasis, including viral distribution and shedding characteristics, as well as immunogenicity. To explore the relationship between pharmacodynamics, biomarkers, and therapeutic efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Doxorubicin (Adriamycin) | Doxorubicin (Adriamycin) |
| DRUG | VRT106 | VRT106 |
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2028-03-01
- Completion
- 2029-06-01
- First posted
- 2026-03-20
- Last updated
- 2026-03-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07486310. Inclusion in this directory is not an endorsement.